ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

(2020) Arthur Bergman et al.   Clinical Pharmacology in Drug Development

Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation

(2020) Jamie Bates et al.   JOURNAL OF HEPATOLOGY

From NAFLD to MAFLD: Implications of a premature change in terminology

(2020) Zobair M Younossi et al.   HEPATOLOGY

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems

(2020) Trenton T. Ross et al.   Cellular and Molecular Gastroenterology and Hepatology

Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial

(2019) Helen Parker et al.   Nutrients

Hepatocyte Deletion of Triglyceride‐Synthesis Enzyme DGAT 2 Reduces Steatosis without Increasing Inflammation or Fibrosis

(2019) Nina L. Gluchowski et al.   HEPATOLOGY

PS-106-An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients

(2019) Rohit Loomba et al.   JOURNAL OF HEPATOLOGY

Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes

(2019) Jenny E. Kanter et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis

(2019) Neeta B. Amin et al.   Science Translational Medicine

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

(2018) Eric J. Lawitz et al.   Clinical Gastroenterology and Hepatology

Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents

(2018) Leigh Goedeke et al.   HEPATOLOGY

Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials

(2018) Cyrielle Caussy et al.   HEPATOLOGY

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

Future trends in the treatment of non-alcoholic steatohepatitis

(2018) Stefano Fiorucci et al.   PHARMACOLOGICAL RESEARCH

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study

(2018) Jan Oscarsson et al.   Journal of Clinical Lipidology

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study

(2017) Kathryn Stiede et al.   HEPATOLOGY

Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults

(2016) Andrea Marengo et al.   Clinics in Liver Disease

Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis

(2016) Janki Patel et al.   Therapeutic Advances in Gastroenterology

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or PlaceboCLINICAL PERSPECTIVE

(2015) Samia Mora et al.   CIRCULATION

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

(2015) Rohit Loomba et al.   HEPATOLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes

(2014) David A. Griffith et al.   JOURNAL OF MEDICINAL CHEMISTRY

Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease

(2013) Jennifer E. Lambert et al.   GASTROENTEROLOGY

Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial

(2012) Thuy-Anh Le et al.   HEPATOLOGY

Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging

(2012) Arian Mashhood et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease

(2010) Elisa Fabbrini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pathogenesis of non-alcoholic fatty liver disease

(2009) J. K. Dowman et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Malonyl-CoA, a Key Signaling Molecule in Mammalian Cells

(2008) David Saggerson   Annual Review of Nutrition

Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver

(2008) Nila Rafiq et al.   Clinical Gastroenterology and Hepatology

Thematic Review Series: Glycerolipids.DGAT enzymes and triacylglycerol biosynthesis

(2008) Chi-Liang Eric Yen et al.   JOURNAL OF LIPID RESEARCH